Article Details

Ventyx Biosciences Doses First Subject in a Phase 1 Trial of VTX-958, a Selective Allosteric TYK2 ...

Retrieved on: 2021-03-16 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

Ventyx Biosciences Doses First Subject in a Phase 1 Trial of VTX-958, a Selective Allosteric TYK2 .... View article details on hiswai:

Excerpt

Ventyx recently completed a $114 million equity financing led by venBio Partners ... Farallon Capital, Vivo Capital, Logos Capital, Qiming Venture Partners USA, ... and participation from founding investor New Science Ventures.

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up